Tag: personalized medicine biomarkers market forecast

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Personalized Medicine Biomarkers Market Size Outlook: How Quickly Will Revenue Expand Through 2030?

The personalized medicine biomarkers market size has experienced rapid growth in recent years. It is projected to expand from $26.73 billion in 2025 to $31.34 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 17.3%. This historical growth can be attributed to advancements in genomic research, an increasing incidence of cancer, the proliferation of targeted therapies, wider application of molecular diagnostics, and supportive regulatory frameworks for precision medicine.

The personalized medicine biomarkers market size is anticipated to experience rapid growth in the upcoming years. It is projected to reach $58.8 billion by 2030, at a compound annual growth rate (CAGR) of 17.0%. This growth during the forecast period is attributed to the expansion of personalized therapeutics, a rising demand for early disease detection, growth in pharmacogenomics, increasing investment in biomarker discovery, and wider adoption across non-oncology indications. Key trends for the forecast period encompass the rising adoption of precision treatment approaches, increasing use of biomarkers in oncology care, growing integration of companion diagnostics, the expansion of predictive and prognostic biomarkers, and a higher focus on treatment response monitoring.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=65633950&type=smp&name=Personalized%20Medicine%20Biomarkers%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Personalized Medicine Biomarkers Market Growth Drivers: What’s Behind The Acceleration?

The increasing occurrence of chronic illnesses is anticipated to boost the expansion of the personalized medicine biomarkers market in the future. Chronic illnesses are enduring health issues characterized by gradual development, lasting a minimum of one year, and necessitating continuous medical care or restricting everyday functions. This rising prevalence of chronic conditions stems from factors such as unhealthy lifestyle choices, poor nutritional habits, insufficient physical exercise, and elevated stress levels. Personalized medicine biomarkers aid in customizing treatments for chronic ailments by pinpointing efficacious therapies, forecasting disease advancement, and reducing negative reactions, all informed by a person’s unique genetic and molecular characteristics. For example, data released in February 2024 by the World Health Organization (WHO), a health authority based in Switzerland, projects that by 2050, new cancer cases will exceed 35 million, which signifies a 77% surge from the approximate 20 million cases recorded in 2022. Consequently, the increasing incidence of chronic diseases is propelling the expansion of the personalized medicine biomarkers market.

Personalized Medicine Biomarkers Market Segment Analysis And Revenue Potential

The personalized medicine biomarkers market covered in this report is segmented –

1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types

2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications

3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring

4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users

Subsegments:

1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers

2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers

3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers

4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers

Personalized Medicine Biomarkers Market Trends: What’s Defining The Industry’s Next Phase?

Leading companies within the personalized medicine biomarkers market are concentrating on securing regulatory authorizations, including companion diagnostic approval, to improve precision oncology by quickly connecting patients with specific therapies. Companion diagnostic approval denotes the official permission granted by a health authority, such as the FDA, for a diagnostic test specifically engineered to identify individuals who would most likely benefit from a certain therapeutic product or face a greater risk of adverse reactions. As an illustration, in August 2024, Illumina, Inc., a US-based biotechnology company, obtained Food and Drug Administration (FDA) approval for its cancer biomarker test and two companion diagnostics. The test employs next-generation sequencing (NGS) technology to find genetic mutations in cancer cells, allowing clinicians to select the most appropriate treatments based on individual biomarkers. This approval signifies a major step forward in precision oncology, intending to enhance the speed and precision of treatment selection for cancer patients, thereby elevating personalized care.

Personalized Medicine Biomarkers Market Key Players Shaping Industry Direction

Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

View The Full Personalized Medicine Biomarkers Market Report:

https://thebusinessresearchcompany.com/report/personalized-medicine-biomarkers-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Personalized Medicine Biomarkers Market Leading Geography: Which Region Contributes The Most Revenue?

North America was the largest region in the personalized medicine biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Personalized Medicine Biomarkers Market Growth From $31.34 Billion In 2026 To $58.79 Billion By 2030 At A CAGR Of 17%

The market for biomarkers in personalized medicine has experienced significant expansion over the past few years. By 2025, its value reached $26.73 billion, and this figure is projected to climb to $31.34 billion by 2026, reflecting a compound annual growth rate (CAGR) of 17.3%. This historic growth has been driven by advancements in genomic research, a growing number of cancer cases, the rise of targeted treatment approaches, broader adoption of molecular diagnostic tools, and supportive regulatory frameworks for precision medicine.

The personalized medicine biomarkers market is projected to experience substantial expansion in the upcoming years, reaching $58.8 billion by 2030 with a compound annual growth rate (CAGR) of 17.0%. This forecasted growth is driven by the expansion of personalized therapeutics, a growing need for early disease detection, advancements in pharmacogenomics, increased funding for biomarker discovery, and broader application in non-oncology indications. Key trends shaping this period include the rising adoption of precision treatment strategies, the growing use of biomarkers in oncology care, the increasing integration of companion diagnostics, the development of both predictive and prognostic biomarkers, and a heightened emphasis on monitoring treatment responses.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Personalized Medicine Biomarkers Market Development Factors: Which Trends Are Supporting Demand?

The rising incidence of chronic illnesses is anticipated to boost the personalized medicine biomarkers market in the coming years. Chronic diseases are long-term health conditions that develop slowly, last a year or longer, and demand ongoing medical care or restrict everyday activities. This increase is mainly driven by poor lifestyle habits, unhealthy diets, insufficient physical activity, and elevated stress levels. Personalized medicine biomarkers facilitate tailored treatments for chronic conditions by pinpointing effective therapies, forecasting disease progression, and reducing negative effects using individual genetic and molecular insights. For example, as reported in February 2024 by the World Health Organization (WHO), a health authority based in Switzerland, new cancer cases worldwide are projected to exceed 35 million by 2050, marking a 77% rise from the roughly 20 million cases recorded in 2022. Consequently, the growing frequency of chronic diseases is fueling expansion in the personalized medicine biomarkers market.

Personalized Medicine Biomarkers Market Categorization By Product Type And Application

The personalized medicine biomarkers market covered in this report is segmented –

1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types

2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications

3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring

4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users

Subsegments:

1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers

2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers

3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers

4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers

Personalized Medicine Biomarkers Market Transformation Trends: Which Innovations Are Driving Change?

Key players in the personalized medicine biomarkers sector are concentrating on securing regulatory clearances, such as companion diagnostic approvals, to advance precision oncology by efficiently linking patients to targeted therapies. This type of approval is an official endorsement from a regulatory body, like the FDA, for a diagnostic tool created to pinpoint individuals who will gain the most from a specific therapeutic product or who face a higher chance of experiencing harmful side effects. In August 2024, for example, Illumina, Inc.—a biotechnology firm based in the United States—obtained FDA approval for its cancer biomarker test along with two companion diagnostics. The test employs next-generation sequencing (NGS) to detect genetic mutations in tumor cells, allowing physicians to choose the best treatments according to each patient’s unique biomarkers. This authorization represents a notable step forward in precision oncology, with the goal of enhancing the speed and precision of treatment decisions for cancer patients, thereby boosting personalized medicine approaches.

Personalized Medicine Biomarkers Market Company Landscape And Strategic Competition

Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

Access The Complete Personalized Medicine Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/personalized-medicine-biomarkers-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Personalized Medicine Biomarkers Market Largest Region: Which Geography Holds The Highest Market Share?

North America was the largest region in the personalized medicine biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Expected Market Value Outlook For The Personalized Medicine Biomarkers Market Through 2030?

The personalized medicine biomarkers market size has shown significant recent growth. It is anticipated to increase from $26.73 billion in 2025 to $31.34 billion in 2026, at a compound annual growth rate (CAGR) of 17.3%. The factors contributing to its historical growth include advances in genomic research, a rising incidence of cancer, the expansion of targeted therapies, increased utilization of molecular diagnostics, and regulatory support for precision medicine.

The personalized medicine biomarkers market is projected to experience substantial expansion in the coming years, with its size expected to reach $58.8 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.0%. This anticipated growth during the forecast period is fueled by several factors, including the increasing use of personalized treatments, a greater need for early disease identification, advancements in pharmacogenomics, increased funding for biomarker research, and broader application in areas beyond oncology. Key trends expected over the forecast period encompass the increasing embrace of precise treatment strategies, the expanded application of biomarkers in cancer care, the deeper incorporation of companion diagnostics, the broader development of predictive and prognostic biomarkers, and a heightened emphasis on tracking treatment effectiveness.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp

Which Significant Factors Are Encouraging Growth In The Personalized Medicine Biomarkers Market?

An increasing incidence of chronic diseases is anticipated to fuel the expansion of the personalized medicine biomarkers market. These conditions are defined as enduring health issues that evolve gradually, lasting a minimum of one year, necessitating continuous medical care, or restricting daily functions. This rise in chronic diseases stems from factors such as poor lifestyle choices, inadequate nutrition, insufficient exercise, and elevated stress levels. Personalized medicine biomarkers facilitate customized treatments for chronic diseases by pinpointing effective remedies, forecasting disease advancement, and reducing negative reactions, all informed by unique genetic and molecular profiles. For example, data from February 2024, released by the World Health Organization (WHO), a health authority located in Switzerland, projects that new cancer cases will exceed 35 million by 2050, marking a 77% rise from the approximately 20 million cases recorded in 2022. Consequently, the increasing occurrence of chronic diseases is a primary catalyst for the expansion of the personalized medicine biomarkers market.

What Segment Types Are Included In The Personalized Medicine Biomarkers Market Analysis?

The personalized medicine biomarkers market covered in this report is segmented –

1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types

2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications

3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring

4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users

Subsegments:

1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers

2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers

3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers

4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers

Which Trends Are Guiding The Development Of The Personalized Medicine Biomarkers Market?

Major companies in the personalized medicine biomarkers market are concentrating on obtaining regulatory approvals, such as companion diagnostic approval, to improve precision oncology by quickly linking patients to appropriate therapies. Companion diagnostic approval refers to the official authorization granted by a health authority (like the FDA) for a diagnostic test specifically designed to determine which patients are most likely to benefit from a particular therapeutic product or face an increased risk of adverse reactions. For instance, in August 2024, Illumina, Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its cancer biomarker test and two companion diagnostics. The test utilizes next-generation sequencing (NGS) technology to detect genetic mutations in cancer cells, allowing clinicians to select the most fitting treatments based on individual biomarkers. This approval signifies a notable progression in precision oncology, aiming to enhance the speed and correctness of treatment selection for cancer patients, ultimately improving personalized care.

Who Are The Key Market Participants In The Personalized Medicine Biomarkers Market?

Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

Access The Complete Personalized Medicine Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/personalized-medicine-biomarkers-global-market-report

Which Region Has The Strongest Presence In The Personalized Medicine Biomarkers Market?

North America was the largest region in the personalized medicine biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Personalized Medicine Biomarkers Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp

Browse Through More Reports Similar to the Global Personalized Medicine Biomarkers Market 2026, By The Business Research Company

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Personalized Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/personalized-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Will The Market Value Of The Personalized Medicine Biomarkers Market Progress Between 2026 And 2030?

The personalized medicine biomarkers market has seen rapid expansion in recent years. Its valuation is projected to increase from $26.73 billion in 2025 to $31.34 billion in 2026, at a compound annual growth rate (CAGR) of 17.3%. The historical growth of this market can be attributed to various factors, including advances in genomic research, a rising incidence of cancer, the expansion of targeted therapies, increased utilization of molecular diagnostics, and regulatory support for precision medicine.

The personalized medicine biomarkers market is projected to experience substantial expansion over the upcoming years, reaching a valuation of $58.8 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.0%. This anticipated growth during the forecast period is primarily driven by factors such as the proliferation of personalized therapeutics, an increasing need for early detection of diseases, advancements in pharmacogenomics, greater investment in the discovery of biomarkers, and broader application across non-oncology areas. Key trends anticipated during the forecast timeframe encompass the increasing embrace of precision treatment methodologies, a greater utilization of biomarkers in cancer care, the expanding integration of companion diagnostics, the development of predictive and prognostic biomarkers, and an intensified emphasis on monitoring treatment responses.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp

What Significant Factors Are Influencing The Personalized Medicine Biomarkers Market Expansion?

The expanding incidence of chronic diseases is anticipated to fuel the expansion of the personalized medicine biomarkers market in the future. These conditions are long-term health issues that develop gradually and endure for a year or longer, necessitating continuous medical care or restricting daily functioning. The increasing occurrence of chronic diseases stems from detrimental lifestyle habits, inadequate nutrition, insufficient physical movement, and elevated stress levels. Personalized medicine biomarkers play a crucial role in customizing treatments for chronic diseases, achieving this by pinpointing effective remedies, forecasting the disease’s advancement, and reducing negative reactions, all informed by a person’s unique genetic and molecular characteristics. As an illustration, in February 2024, the World Health Organization (WHO), a Switzerland-based health authority, projected that new cancer cases would exceed 35 million by 2050, marking a 77% rise from the approximately 20 million cases recorded in 2022. Consequently, the rising occurrence of chronic diseases is propelling the growth of the personalized medicine biomarkers market.

Which Segment Categories Are Included In The Personalized Medicine Biomarkers Market Segment Analysis?

The personalized medicine biomarkers market covered in this report is segmented –

1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types

2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications

3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring

4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users

Subsegments:

1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers

2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers

3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers

4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers

Which Trends Are Impacting The Progress Of The Personalized Medicine Biomarkers Market?

Leading companies operating in the personalized medicine biomarkers market are seeking regulatory approvals, such as companion diagnostic approval, to enhance precision oncology by more effectively matching patients to targeted therapies. Companion diagnostic approval refers to the regulatory authorization issued by a health authority (such as the FDA) for a diagnostic test specifically designed to identify patients most likely to benefit from a particular therapeutic product or those at increased risk of adverse reactions. For instance, in August 2024, Illumina, Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its cancer biomarker test and two companion diagnostics. The test utilizes next-generation sequencing (NGS) technology to pinpoint genetic mutations in cancer cells, thereby enabling clinicians to select the most suitable treatments based on individual biomarkers. This approval signifies a substantial advancement in precision oncology, aiming to improve the speed and accuracy of treatment selection for cancer patients, thereby enhancing personalized care.

Who Are The Active Companies Shaping The Personalized Medicine Biomarkers Market?

Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

Get The Full Personalized Medicine Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/report/personalized-medicine-biomarkers-global-market-report

Which Region Is The Leading Market For The Personalized Medicine Biomarkers Market?

North America was the largest region in the personalized medicine biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Personalized Medicine Biomarkers Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/personalized-medicine-biomarkers-global-market-report

Browse Through More Reports Similar to the Global Personalized Medicine Biomarkers Market 2026, By The Business Research Company

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Personalized Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/personalized-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Estimated Market Size Of The Personalized Medicine Biomarkers Market During 2026–2030?

The personalized medicine biomarkers market has experienced rapid expansion in recent years. It is projected to increase from $26.73 billion in 2025 to $31.34 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 17.3%. The historical development of this market is primarily due to advances in genomic research, a rise in cancer incidence, the proliferation of targeted therapies, enhanced utilization of molecular diagnostics, and strong regulatory support for precision medicine.

The personalized medicine biomarkers market size is set to experience swift expansion in the coming years. This market is projected to reach $58.8 billion by 2030, showing a compound annual growth rate (CAGR) of 17.0%. The anticipated growth over the forecast period stems from the broader implementation of personalized therapeutics, a rising need for early disease detection, advancements in pharmacogenomics, increased investment in biomarker discovery, and wider acceptance across non-oncology indications. Prominent trends for this period include the growing embrace of precision treatment strategies, expanded application of biomarkers in oncology care, increasing incorporation of companion diagnostics, the proliferation of predictive and prognostic biomarkers, and a heightened emphasis on monitoring treatment response.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp

What Underlying Factors Are Accelerating The Growth Of The Personalized Medicine Biomarkers Market?

The increasing occurrence of chronic diseases is anticipated to boost the expansion of the personalized medicine biomarkers market in the future. These enduring health conditions advance gradually, lasting for at least a year, and necessitate continuous medical care or restrict daily life. This rise in chronic disease prevalence stems from poor lifestyle choices, inadequate nutrition, insufficient physical activity, and elevated stress levels. Personalized medicine biomarkers are instrumental in customizing treatments for chronic conditions by pinpointing effective therapies, forecasting disease progression, and reducing negative side effects, all based on a person’s unique genetic and molecular makeup. A relevant illustration comes from February 2024, when the World Health Organization (WHO), a Switzerland-based health authority, projected that by 2050, new cancer cases would exceed 35 million, marking a 77% surge from the approximate 20 million cases in 2022. Consequently, the expanding presence of chronic diseases is fueling the growth of the personalized medicine biomarkers market.

How Are The Various Segments Of The Personalized Medicine Biomarkers Market Categorized?

The personalized medicine biomarkers market covered in this report is segmented –

1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types

2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications

3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring

4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users

Subsegments:

1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers

2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers

3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers

4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers

What Trends Are Affecting The Expansion Of The Personalized Medicine Biomarkers Market?

Leading companies in the personalized medicine biomarkers market are concentrating on acquiring regulatory authorizations, including companion diagnostic approval, to bolster precision oncology by swiftly connecting patients with targeted treatments. Companion diagnostic approval signifies the official permission granted by a health authority, such as the FDA, for a diagnostic test specifically designed to identify patients most likely to benefit from a particular therapeutic product or those at higher risk of adverse reactions. For example, in August 2024, Illumina, Inc., a US-based biotechnology company, obtained Food and Drug Administration (FDA) approval for its cancer biomarker test alongside two companion diagnostics. This test employs next-generation sequencing (NGS) technology to detect genetic mutations in cancer cells, empowering clinicians to select the most appropriate treatments based on individual biomarkers. This regulatory clearance signifies a substantial leap forward in precision oncology, aiming to enhance the swiftness and precision of treatment selection for cancer patients, ultimately improving personalized care.

Which Major Firms Influence Developments In The Personalized Medicine Biomarkers Market?

Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

Read the full personalized medicine biomarkers market report here:

https://www.thebusinessresearchcompany.com/report/personalized-medicine-biomarkers-global-market-report

Which Region Is Projected To Dominate The Personalized Medicine Biomarkers Market During The Forecast Period?

North America was the largest region in the personalized medicine biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Personalized Medicine Biomarkers Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23471&type=smp

Browse Through More Reports Similar to the Global Personalized Medicine Biomarkers Market 2026, By The Business Research Company

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Personalized Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/personalized-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the personalized medicine biomarkers market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Personalized Medicine Biomarkers Market between 2026 and 2030?

The personalized medicine biomarkers market has shown significant growth in recent years. Its valuation is anticipated to rise from $26.73 billion in 2025 to $31.34 billion by 2026, achieving a compound annual growth rate (CAGR) of 17.3%. Historically, this expansion has been driven by progress in genomic research, an uptick in cancer cases, the development of targeted therapies, increased application of molecular diagnostics, and favorable regulatory environments for precision medicine.

The personalized medicine biomarkers market is projected to experience substantial expansion in the coming years, with its size expected to reach $58.8 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 17.0%. This anticipated growth can be attributed to factors such as the wider application of personalized therapeutics, a greater demand for early disease detection, advancements in pharmacogenomics, increased investment in biomarker discovery, and broader adoption across non-oncology indications. Significant trends identified for this period include the increasing embrace of precision treatment approaches, the expanded utilization of biomarkers in oncology care, the growing integration of companion diagnostics, the broadened utility of predictive and prognostic biomarkers, and a heightened focus on monitoring treatment responses.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Personalized Medicine Biomarkers Market?

The escalating incidence of chronic diseases is projected to drive the growth within the personalized medicine biomarkers market. Chronic diseases are defined as protracted medical conditions that progress slowly and endure for a year or more, demanding ongoing medical care or limiting daily functions. The increasing occurrence of these conditions is attributed to unhealthy lifestyle choices, poor dietary habits, insufficient physical activity, and heightened stress levels. Personalized medicine biomarkers play a crucial role in tailoring treatments for chronic illnesses by identifying effective therapies, forecasting disease progression, and minimizing adverse reactions based on individual genetic and molecular profiles. For instance, in February 2024, the World Health Organization (WHO), a health authority located in Switzerland, indicated that new cancer cases are expected to exceed 35 million by 2050, representing a 77% increase from the estimated 20 million cases in 2022. Therefore, the expanding prevalence of chronic diseases is propelling the personalized medicine biomarkers market.

How Is The Personalized Medicine Biomarkers Market Organized Into Various Segments?

The personalized medicine biomarkers market covered in this report is segmented –

1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types

2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications

3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring

4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users

Subsegments:

1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers

2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers

3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers

4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers

Which Innovation Trends Are Advancing Developments Within The Personalized Medicine Biomarkers Market?

Companies operating within the personalized medicine biomarkers market are increasingly focused on acquiring regulatory authorizations, such as companion diagnostic approval, to improve precision oncology by efficiently linking patients to specific targeted therapies. Companion diagnostic approval refers to the official permission granted by a health authority, like the FDA, for a diagnostic test specifically engineered to identify patients most likely to benefit from a particular therapeutic product or those at an elevated risk of adverse reactions. For instance, in August 2024, Illumina, Inc., a US-based biotechnology company, received Food and Drug Administration (FDA) approval for its cancer biomarker test and two companion diagnostics. This test employs next-generation sequencing (NGS) technology to detect genetic mutations in cancer cells, thereby enabling clinicians to select the most appropriate treatments based on individual biomarkers. This approval signifies a substantial leap forward in precision oncology, aiming to enhance both the speed and accuracy of treatment selection for cancer patients, ultimately improving personalized care.

Who Are The Prominent Global Companies Shaping The Personalized Medicine Biomarkers Market Landscape?

Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/personalized-medicine-biomarkers-global-market-report

Which Geographic Areas Are Emerging As Strong Markets For The Personalized Medicine Biomarkers Market?

North America was the largest region in the personalized medicine biomarkers market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Personalized Medicine Biomarkers Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=23471&type=smp

Browse Through More Reports Similar to the Global Personalized Medicine Biomarkers Market 2026, By The Business Research Company

Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Clinical Biomarkers Market Report 2026

https://www.thebusinessresearchcompany.com/report/clinical-biomarkers-global-market-report

Personalized Medicine Market Report 2026

https://www.thebusinessresearchcompany.com/report/personalized-medicine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the anticholinergic drugs market from 2025–2034 with trusted insights from The Business Research Company

How Much Will The Anticholinergic Drugs Market Be Worth By 2029, And What CAGR Will It Achieve?

The personalized medicine biomarkers market has seen rapid expansion in recent years. This market is projected to expand from $22.85 billion in 2024 to $26.73 billion in 2025, exhibiting a compound annual growth rate (CAGR) of 17.0%. Its historical growth can be attributed to several factors, including the increasing prevalence of chronic diseases, a rise in the adoption of companion diagnostics, growing investment in biomarker research, an increased focus on early diagnosis and preventive healthcare, and supportive regulatory frameworks for biomarker-based therapies.

The personalized medicine biomarkers market size is anticipated to experience significant expansion over the next few years. It is projected to reach $50.33 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 17.1%. This growth during the forecast period is attributable to the increasing applications in precision oncology, a rising demand for targeted therapies, a heightened focus on early disease detection, growing consumer interest in personalized medical approaches, and supportive government policies and funding. Significant trends expected in the forecast period include the adoption of a multi-omics approach for biomarker identification, the advancement of liquid biopsy-based biomarkers, the expanded use of digital biomarkers, the integration of AI and machine learning in biomarker discovery, and the broader application of real-world evidence in biomarker validation.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp

Which Factors Are Driving The Anticholinergic Drugs Market Forward?

An increasing incidence of chronic illnesses is anticipated to fuel the expansion of the personalized medicine biomarkers market moving ahead. These conditions are defined as long-lasting health issues that develop gradually and endure for at least a year, necessitating continuous healthcare or restricting daily functions. The rise in chronic disease prevalence stems from factors such as poor lifestyle decisions, inadequate nutrition, insufficient physical exercise, and elevated stress levels. Personalized medicine biomarkers facilitate the customization of treatments for chronic ailments by pinpointing effective therapies, forecasting disease advancement, and reducing negative side effects, all informed by an individual’s unique genetic and molecular characteristics. For example, data from February 2024, supplied by the World Health Organization (WHO), a health body located in Switzerland, projects that by the year 2050, newly diagnosed cancer cases will exceed 35 million, marking a 77% surge from the approximate 20 million cases recorded in 2022. Consequently, the expanding occurrence of chronic illnesses is accelerating the development of the personalized medicine biomarkers market.

Which Segments Form The Key Structure Of The Anticholinergic Drugs Market?

The personalized medicine biomarkers market covered in this report is segmented –

1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types

2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications

3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring

4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users

Subsegments:

1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers

2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers

3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers

4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers

What Strategic Shifts And Innovations Are Influencing The Anticholinergic Drugs Market?

Leading companies operating within the personalized medicine biomarkers market are concentrating on securing regulatory approvals to bolster their products’ credibility, broaden their market footprint, and enhance patient outcomes. Regulatory approvals represent the official endorsement from health authorities, affirming that a medical product, treatment, or technology fulfills safety, efficacy, and quality criteria for public consumption. For instance, in August 2024, Illumina, Inc., a US-based biotechnology company, obtained Food and Drug Administration (FDA) approval for its cancer biomarker test and two companion diagnostics. This test employs next-generation sequencing (NGS) technology to identify genetic mutations in cancer cells, allowing clinicians to select the most appropriate treatments based on individual biomarkers. This approval signifies a substantial progression in precision oncology, aiming to improve the pace and accuracy of treatment selection for cancer patients, thereby elevating personalized care.

Which Firms Are Making The Biggest Impact In The Anticholinergic Drugs Market?

Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/personalized-medicine-biomarkers-global-market-report

Which Region Is Expected To Lead The Anticholinergic Drugs Market In The Next Few Years?

North America was the largest region in the personalized medicine biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=23471&type=smp

Browse Through More Reports Similar to the Global Anticholinergic Drugs Market 2025, By The Business Research Company

Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Renal Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Cancer Biomarker Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Expected Total Market Size Of The Personalized Medicine Biomarkers Industry By The Forecast Year 2029?

The personalized medicine biomarkers market has seen rapid expansion in recent years. Its size is expected to increase from $22.85 billion in 2024 to $26.73 billion in 2025, progressing at a compound annual growth rate (CAGR) of 17.0%. This historical development can be attributed to the increasing prevalence of chronic diseases, rising adoption of companion diagnostics, growing investment in biomarker research, rising focus on early diagnosis and preventive healthcare, and regulatory support for biomarker-based therapies.

The market for personalized medicine biomarkers is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $50.33 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 17.1%. Factors contributing to this growth throughout the forecast period include the expanding utility in precision oncology, rising need for targeted therapies, increased emphasis on early disease detection, escalating consumer preference for personalized methods, and favorable government policies along with financial support. Key trends emerging during this forecast timeframe encompass the implementation of multi-omics strategies for biomarker identification, the advancement of liquid biopsy-derived biomarkers, the growing application of digital biomarkers, the integration of AI and machine learning in the discovery of biomarkers, and the broader incorporation of real-world evidence in biomarker validation.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp

What Are The Main Drivers Boosting The Personalized Medicine Biomarkers Industry’s Expansion?

The increasing incidence of chronic illnesses is anticipated to drive the expansion of the personalized medicine biomarkers market in the future. These conditions are defined as enduring health issues that evolve gradually and persist for at least a year, necessitating continuous healthcare or restricting everyday functions. This rise in chronic disease prevalence stems from poor lifestyle decisions, inadequate nutrition, insufficient physical exercise, and elevated stress levels. Personalized medicine biomarkers facilitate the customization of treatments for chronic ailments through the identification of effective therapies, forecasting disease advancement, and reducing negative side effects, all informed by individual genetic and molecular profiles. As an illustration, in February 2024, the World Health Organization (WHO), a health authority located in Switzerland, projected that new cancer diagnoses would exceed 35 million by 2050, marking a 77% surge from the approximate 20 million cases reported in 2022. Consequently, the escalating occurrence of chronic diseases is fueling the expansion of the personalized medicine biomarkers market.

How Is The Personalized Medicine Biomarkers Market Segmented?

The personalized medicine biomarkers market covered in this report is segmented –

1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types

2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications

3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring

4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users

Subsegments:

1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers

2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers

3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers

4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers

What Are The Major Trends Driving The Growth Of The Personalized Medicine Biomarkers Market?

Major companies operating in the personalized medicine biomarkers market are focusing on obtaining regulatory approvals to enhance the credibility of their products, expand their market presence, and improve patient outcomes. Regulatory approvals refer to the official authorization of health authorities, confirming that a medical product, treatment, or technology meets safety, efficacy, and quality standards for public use. For instance, in August 2024, Illumina, Inc., a US-based biotechnology company, received the Food and Drug Administration (FDA) approval for its cancer biomarker test and two companion diagnostics. The test uses next-generation sequencing (NGS) technology to identify genetic mutations in cancer cells, enabling clinicians to select the most suitable treatments based on individual biomarkers. This approval marks a significant advancement in precision oncology, aiming to improve the speed and accuracy of treatment selection for cancer patients, ultimately enhancing personalized care.

Which Global Market Leaders Are Shaping The Future Of The Personalized Medicine Biomarkers Sector?

Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/personalized-medicine-biomarkers-global-market-report

Which Region Is Expected To Witness The Fastest Growth In The Personalized Medicine Biomarkers Market?

North America was the largest region in the personalized medicine biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Personalized Medicine Biomarkers Market Report:

https://www.thebusinessresearchcompany.com/customise?id=23471&type=smp

Browse Through More Reports Similar to the Global Personalized Medicine Biomarkers Market 2025, By The Business Research Company

Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/biomarkers-global-market-report

Renal Biomarkers Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/renal-biomarkers-global-market-report

Cancer Biomarker Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim 30% Off Global Market Reports With Code ONLINE30 – Insights on Tariff Effects, Global Trade, and Industry Disruptors

What Is The Predicted Market Size Of The Personalized Medicine Biomarkers Industry By 2029?

The market size for personalized medicine biomarkers has seen substantial growth in recent times. It is projected to increase from $22.85 billion in 2024 to $26.73 billion in 2025, with a compound annual growth rate (CAGR) of 17.0%. The growth experienced in the previous period is due to the rising occurrence of chronic illnesses, increased usage of companion diagnostics, growing funding dedicated for biomarker research, an increased emphasis on early diagnostic measures and preventive healthcare, as well as regulatory encouragement for therapies based on biomarkers.

In the coming years, the market size of personalized medicine biomarkers is set to experience substantial growth, reaching $50.33 billion in 2029 with a compound annual growth rate (CAGR) of 17.1%. The forecasted growth can be linked to numerous factors including the widening applications in precision oncology, rising demand for targeted treatments, increasing emphasis on early disease identification, growing consumer preference for personalized treatments, and supportive government initiatives and funds. Key trends anticipated during this forecasted period encompass a multi-omics approach to identify biomarkers, the evolution of liquid biopsy-based biomarkers development, the growing application of digital biomarkers, the increased use of AI and machine learning in the discovery of biomarkers, and the broadening use of real-world evidence for biomarker verification.

Get A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp

Which Industry Forces Are Driving The Personalized Medicine Biomarkers Market Forward?

The surge in chronic diseases is predicted to fuel the expansion of the personalized medicine biomarkers market. Chronic diseases are slow-progressing, long-term health conditions that last over a year and require consistent medical care or impact daily activities. This surge is attributed to unhealthy lifestyle choices, poor diets, lack of physical activity, and elevated stress levels. Personalized medicine biomarkers facilitate tailored treatments for chronic diseases by pinpointing effective therapies, anticipating disease progression, and reducing unfavourable effects based on personalized genetic and molecular profiles. For example, the World Health Organization (WHO), a Switzerland-based health authority, stated in February 2024 that the number of new cancer cases is anticipated to exceed 35 million by 2050, indicating a 77% surge from the projected 20 million cases in 2022. Hence, the surge in chronic diseases is propelling the personalized medicine biomarkers market’s expansion.

How Is The Personalized Medicine Biomarkers Market Organized By Different Segments?

The personalized medicine biomarkers market covered in this report is segmented –

1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types

2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications

3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring

4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users

Subsegments:

1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers

2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers

3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers

4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers

What Current And Upcoming Trends Are Shaping The Personalized Medicine Biomarkers Market?

Key enterprises in the personalized medicine biomarkers sector are concentrating their efforts on securing regulatory authorizations. This strategy is aimed at boosting the reputation of their products, enlarging their market share, and advancing patient outcomes. Regulatory approvals are endorsements from health entities, attesting that a medical product, procedure, or technology adheres to safety, effectiveness, and quality standards for public use. For example, in August 2024, Illumina, Inc., a US-based biotech firm, was granted approval by the Food and Drug Administration (FDA) for its cancer biomarker examination and a pair of companion diagnostics. The test implements next-generation sequencing (NGS) technology to detect genetic anomalies in cancer cells, thereby assisting healthcare professionals in choosing the optimal treatments based on individual biomarkers. This clearance represents a vital progress in precision oncology, striving to elevate the efficiency and precision of treatment choice for cancer patients, ultimately promoting personalized healthcare.

Which Firms Are Making The Biggest Impact In The Personalized Medicine Biomarkers Market?

Major companies operating in the personalized medicine biomarkers market are AbbVie Inc., Bristol-Myers Squibb Company, Thermo Fisher Scientific Inc., Abbott Laboratories, Novartis AG, Merck KGaA, GE Healthcare, Laboratory Corporation of America Holdings (LabCorp), Agilent Technologies Inc., Hologic Inc., Illumina Inc., PerkinElmer Inc., Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., DH Life Sciences LLC, Myriad Genetics Inc., Guardant Health Inc., Cardiff Oncology Inc., 23andMe Inc., Coriell Life Sciences Inc.

Access The Complete Report Here:

https://www.thebusinessresearchcompany.com/report/personalized-medicine-biomarkers-global-market-report

Which Region Dominates The Personalized Medicine Biomarkers Market Today?

North America was the largest region in the personalized medicine biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Customize Your Report Here:

https://www.thebusinessresearchcompany.com/customise?id=23471&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Key Projections for the CAGR of the Personalized Medicine Biomarkers Market Size From 2025 to 2034?

The market for personalized medicine biomarkers has seen a rather quick expansion in the past few years. The market is projected to increase from $22.85 billion in 2024 to $26.73 billion in 2025, reflecting a compound annual growth rate (CAGR) of 17.0%. The growth in the historic period can be largely linked to a rise in chronic diseases, the widespread acceptance of companion diagnostics, an increase in funding in biomarker research, a heightened emphasis on early diagnosis and preventive healthcare, and regulatory backing for biomarker-centric treatments.

The market for personalized medicine biomarkers is projected to experience a rapid expansion over the upcoming years, growing to $50.33 billion by 2029 with a Compound Annual Growth Rate (CAGR) of 17.1%. The asserted growth during the projection period can be ascribed to the broadening applications in precision oncology, surging demand for targeted therapies, increasing emphasis on early detection of diseases, rising consumer preference for personalized methods, and the support offered by governmental policies and funding. The forecast period is marked by significant trends, including the use of a multi-omics strategy for identifying biomarkers, the creation of liquid biopsy-based biomarkers, the accelerated use of digital biomarkers, the incorporation of AI and machine learning in biomarker discovery, and the growth of real-world evidence in biomarker validation.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=23471&type=smp

What are the Fundamental Drivers and Innovations Shaping the Personalized Medicine Biomarkers Market?

The increase in chronic illnesses is anticipated to stimulate the expansion of the personalized medicine biomarkers market. Chronic illnesses, which progress at a slow pace and persist for over a year, demand continuous medical care and restrict day-to-day activities. An unhealthy lifestyle, substandard diets, a lack of physical activity, and elevated stress levels contribute to the rising incident rates of these chronic diseases. Personalized medicine biomarkers facilitate the customization of treatments for chronic conditions by identifying efficacious therapies, forecasting disease trajectory, and reducing harmful reactions based on an individual’s unique genetic and molecular profile. For example, the World Health Organization (WHO), a Switzerland-based health authority, reported in February 2024, that by 2050, new cancer instances are anticipated to cross 35 million, reflecting a 77% growth from the expected 20 million cases in 2022. Therefore, the rising prevalence of chronic diseases is accelerating the expansion of the personalized medicine biomarkers market.

How Is the Personalized Medicine Biomarkers Market Segmented?

The personalized medicine biomarkers market covered in this report is segmented –

1) By Biomarker Type: Genomic, Proteomics, Metabolic, Other Biomarker Types

2) By Disease Indication: Oncology, Neurology, Diabetes, Autoimmune Diseases, Cardiology, Other Indications

3) By Application: Early Detection Or Screening, Diagnosis, Treatment Selection, Monitoring

4) By End Use: Hospitals And Clinics, Pharmaceutical And Biotechnology Companies, Diagnostic Labs, Other End Users

Subsegments:

1) By Genomic: Single Nucleotide Polymorphisms (SNPs), Copy Number Variations (CNVs), Gene Expression Biomarkers, Epigenetic Biomarkers

2) By Proteomics: Protein Expression Biomarkers, Post-Translational Modification (PTM) Biomarkers, Protein-Protein Interaction Biomarkers, Enzyme Activity Biomarkers

3) By Metabolic: Lipid Biomarkers, Amino Acid Biomarkers, Carbohydrate Biomarkers, Hormone Biomarkers

4) By Other Biomarker Types: Inflammatory Biomarkers, Microbiome Biomarkers, Autoantibody Biomarkers, Extracellular Vesicle Biomarkers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=23471&type=smp

Which Regions Are Driving the Next Phase of the Personalized Medicine Biomarkers Market Growth?

North America was the largest region in the personalized medicine biomarkers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the personalized medicine biomarkers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Key Trends Are Shaping the Future of the Personalized Medicine Biomarkers Market?

Major firms in the personalized medicine biomarkers sector are prioritizing obtaining regulatory certifications to bolster the credibility of their offerings, broaden their market footprint, and elevate patient results. These regulatory certifications are the formal endorsements from health regulatory bodies, affirming that a healthcare product, procedure, or technology complies with safety, effectiveness, and quality norms for public use. For example, in August 2024, the U.S.-based biotech firm, Illumina, Inc., achieved the Food and Drug Administration (FDA) approval for its cancer biomarker test and two associated diagnostics. The test employs next-generation sequencing (NGS) technology to spot genetic mutations in cancerous cells, thereby equipping healthcare professionals with the knowledge to choose the most appropriate treatments based on distinctive biomarkers. This approval signifies a notable progression in precision oncology, aimed at augmenting the pace and precision of treatment selection for cancer patients, eventually boosting personalized healthcare.

View the full report here:

https://www.thebusinessresearchcompany.com/report/personalized-medicine-biomarkers-global-market-report

How Is the Personalized Medicine Biomarkers Market Defined and What Are Its Core Parameters?

Personalized medicine biomarkers are specific biological indicators that tailor medical treatments to individual patients based on their unique genetic, molecular, or physiological characteristics. These biomarkers can help predict how a patient will respond to a particular drug, enabling doctors to choose the most effective and safest treatment options.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23471

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model